NAFLD, NASH and Liver Cancer

Overview

Journal Nat Rev Gastroenterol Hepatol

Specialty Gastroenterology

Date 2013 Oct 2

PMID 24080776

Citations 477

Authors

Gregory A Michelotti

Mariana V Machado

Anna Mae Diehl

Affiliations

Soon will be listed here.

Abstract

NAFLD affects a large proportion of the US population and its incidence and prevalence are increasing to epidemic proportions around the world. As with other liver diseases that cause cirrhosis, NAFLD increases the risk of liver cancer, a disease with poor outcomes and limited therapeutic options. The incidences of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma are also rising, and HCC is now the leading cause of obesity-related cancer deaths in middle-aged men in the USA. In this Review, we summarize the correlations between liver cancer and NAFLD-related cirrhosis, and the role of the metabolic syndrome in the development of liver cancer from diverse aetiologies, including HCV-mediated cirrhosis. Recent advances in understanding the progression of NAFLD to HCC from preclinical models will also be discussed. Targeted genetic manipulation of certain metabolic or stress-response pathways, including one-carbon metabolism, NF-κB, PTEN and microRNAs, has been valuable in elucidating the pathways that regulate carcinogenesis in NAFLD. Although tremendous advances have occurred in the identification of diagnostic and therapeutic opportunities to reduce the progression of NAFLD, considerable gaps in our knowledge remain with regard to the mechanisms by which NAFLD and its risk factors promote liver cancer.

Citing Articles

The Immune-Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel Immunotherapies.

Cammarota A, Balsano R, Pressiani T, Bozzarelli S, Rimassa L, Lleo A Cancers (Basel). 2025; 17(2).

PMID: 39858054 PMC: 11763448. DOI: 10.3390/cancers17020272.

Gut Microbiome Modulation in Hepatocellular Carcinoma: Preventive Role in NAFLD/NASH Progression and Potential Applications in Immunotherapy-Based Strategies.

Monti E, Vianello C, Leoni I, Galvani G, Lippolis A, DAmico F Cells. 2025; 14(2).

PMID: 39851512 PMC: 11764391. DOI: 10.3390/cells14020084.

Impact of diabetes on long-term survival in elderly liver cancer patients: A retrospective study.

Chen D, Gao X, Wang Y Open Med (Wars). 2025; 20(1):20241096.

PMID: 39822990 PMC: 11737364. DOI: 10.1515/med-2024-1096.

Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States.

Zhang F, Liu L, Li W Nutr J. 2025; 24(1):6.

PMID: 39810142 PMC: 11730808. DOI: 10.1186/s12937-025-01081-0.

Glucosylceramide Synthase Inhibition in Combination with Aripiprazole Sensitizes Hepatocellular Cancer Cells to Sorafenib and Doxorubicin.

Jennemann R, Volz M, Frias-Soler R, Schulze A, Richter K, Kaden S Int J Mol Sci. 2025; 26(1.

PMID: 39796160 PMC: 11720485. DOI: 10.3390/ijms26010304.

References

Podsypanina K, Ellenson L, Nemes A, Gu J, Tamura M, Yamada K . Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A. 1999; 96(4):1563-8. PMC: 15517. DOI: 10.1073/pnas.96.4.1563. View

Maehama T, Dixon J . The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998; 273(22):13375-8. DOI: 10.1074/jbc.273.22.13375. View

Zhang N, Sun Q, Chen Z, Liu F, Jiang Y . Homeostatic regulatory role of Pokemon in NF-κB signaling: stimulating both p65 and IκBα expression in human hepatocellular carcinoma cells. Mol Cell Biochem. 2012; 372(1-2):57-64. DOI: 10.1007/s11010-012-1445-1. View

Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F . TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell. 2010; 17(5):481-96. DOI: 10.1016/j.ccr.2010.03.021. View

Hu T, Huang C, Lin P, Chang H, Ger L, Lin Y . Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer. 2003; 97(8):1929-40. DOI: 10.1002/cncr.11266. View

Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I . Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab. 2011; 96(8):2601-8. DOI: 10.1210/jc.2010-2415. View

Tsai W, Hsu S, Hsu C, Lai T, Chen S, Shen R . MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012; 122(8):2884-97. PMC: 3408747. DOI: 10.1172/JCI63455. View

Malato Y, Ehedego H, Al-Masaoudi M, Cubero F, Bornemann J, Gassler N . NF-κB essential modifier is required for hepatocyte proliferation and the oval cell reaction after partial hepatectomy in mice. Gastroenterology. 2012; 143(6):1597-1608.e11. DOI: 10.1053/j.gastro.2012.08.030. View

Stiles B, Wang Y, Stahl A, Bassilian S, Lee W, Kim Y . Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A. 2004; 101(7):2082-7. PMC: 357055. DOI: 10.1073/pnas.0308617100. View

10.

Richardson M, Jonsson J, Powell E, Brunt E, Neuschwander-Tetri B, Bhathal P . Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology. 2007; 133(1):80-90. DOI: 10.1053/j.gastro.2007.05.012. View

11.

Lee J, Chu I, Mikaelyan A, Calvisi D, Heo J, Reddy J . Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet. 2004; 36(12):1306-11. DOI: 10.1038/ng1481. View

12.

Malik S, Gupte P, de Vera M, Ahmad J . Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2009; 7(7):800-6. DOI: 10.1016/j.cgh.2009.02.025. View

13.

Teng Y, Mehedint M, Garrow T, Zeisel S . Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas. J Biol Chem. 2011; 286(42):36258-67. PMC: 3196139. DOI: 10.1074/jbc.M111.265348. View

14.

Koh W, Wang R, Jin A, Yu M, Yuan J . Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Br J Cancer. 2013; 108(5):1182-8. PMC: 3619062. DOI: 10.1038/bjc.2013.25. View

15.

Valenti L, Dongiovanni P, Ginanni Corradini S, Burza M, Romeo S . PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease. Dig Liver Dis. 2013; 45(8):619-24. DOI: 10.1016/j.dld.2012.12.006. View

16.

Yang H, Fang F, Chang R, Yang L . MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology. 2013; 58(1):205-17. DOI: 10.1002/hep.26315. View

17.

Karin M . NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol. 2010; 1(5):a000141. PMC: 2773649. DOI: 10.1101/cshperspect.a000141. View

18.

Yang H, Cho M, Li T, Peng H, Ko K, Mato J . MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J Clin Invest. 2012; 123(1):285-98. PMC: 3533284. DOI: 10.1172/JCI63861. View

19.

Liao Y, Liu S, Lee C, Yen C, Chuang P, Chen C . Characterization of a glycine N-methyltransferase gene knockout mouse model for hepatocellular carcinoma: Implications of the gender disparity in liver cancer susceptibility. Int J Cancer. 2008; 124(4):816-26. DOI: 10.1002/ijc.23979. View

20.

Trotman L, Niki M, Dotan Z, Koutcher J, Di Cristofano A, Xiao A . Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003; 1(3):E59. PMC: 270016. DOI: 10.1371/journal.pbio.0000059. View